{"id":8218,"date":"2023-08-04T13:15:25","date_gmt":"2023-08-04T13:15:25","guid":{"rendered":"https:\/\/www.caltagmedsystems.co.uk\/information\/?p=8218"},"modified":"2023-08-04T13:15:25","modified_gmt":"2023-08-04T13:15:25","slug":"hvem-btla-light-cd160-network","status":"publish","type":"post","link":"https:\/\/www.caltagmedsystems.co.uk\/information\/hvem-btla-light-cd160-network\/","title":{"rendered":"HVEM \u2013 BTLA \u2013 LIGHT \u2013 CD160 Network"},"content":{"rendered":"\n
\"\"<\/a><\/figure>\n\n\n\n

HVEM (CD270; TNFRSF14) is a molecular switch that acts both as an immune system stimulator and as an inhibitor. It is expressed in T cells, B cells, natural killer cells, dendritic cells and endothelial cells. LIGHT is an immune stimulator that contributes to dendritic cell maturation and T cell expansion. The immune suppressor BTLA functions in opposition to LIGHT in the suppression of na\u00efve T cell expansion and induction of Treg cells. CD160 acts as an immune suppressor through its interactions with HVEM. The checkpoint receptors\/ligands system HVEM, LIGHT, CD160 and BTLA (CD272) is part of a complex network of overlapping receptor interactions that function in both immune stimulation and suppression and which is a potential therapeutic target for the treatment of autoimmune diseases and allergies and controlling antitumour responses.<\/p>\n\n\n\n

LIT:<\/strong>\u00a0Identification of CD112R as a novel checkpoint for human T cells: Y. Zhu, et al.; J. Exp. Med.\u00a0213,<\/strong>\u00a0167 (2016) \u2022 Cosignaling molecules around LIGHT-HVEMBTLA: from immune activation to therapeutic targeting: C. Pasero, et al.; Curr. Mol. Med.\u00a09,<\/strong>\u00a0911 (2009) \u2022 HVEM\/LIGHT\/BTLA\/CD160 cosignaling pathways as targets for immune regulation: M.L. del Rio, et al.; J. Leukoc. Biol.\u00a087,<\/strong>\u00a0223 (2010)<\/p>\n\n\n\n

Biologically Active\u00a0HVEM, BTLA, CD160 and LIGHT Proteins<\/strong><\/p>\n\n\n\n

See all Biologically Active\u00a0HVEM Proteins\u00a0here<\/a>.<\/p>\n\n\n\n

See all Biologically Active\u00a0BTLA Proteins\u00a0here<\/a>.<\/p>\n\n\n\n

See all Biologically Active\u00a0CD160 Proteins\u00a0here<\/a>.<\/p>\n\n\n\n

See all Biologically Active LIGHT Proteins\u00a0here<\/a>.<\/p>\n\n\n\n

VALIDATED\u00a0Antibodies for BTLA and HVEM Research<\/strong><\/p>\n\n\n\n

See all VALIDATED\u00a0Antibodies for BTLA Research by AdipoGen Life Sciences here<\/a>.<\/p>\n\n\n\n

See all VALIDATED\u00a0Antibodies for BTLA Research by Ancell here<\/a>.<\/p>\n\n\n\n

See all VALIDATED\u00a0Antibodies for HVEM Research here<\/a>.<\/p>\n\n\n\n

\n
Back to T Cell Immune Checkpoints for Immuno-Oncology Research<\/strong><\/a><\/div>\n<\/div>\n\n\n\n

Originally posted on\u00a0adipogen.com\/hvem-btla-light-cd160-network\/<\/a><\/p>\n\n\n\n

Caltag Medsystems <\/a>is the distributor of Adipogen<\/a> products in the UK and Ireland. If you have any questions about these products, please contact<\/a> us<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

The checkpoint receptors\/ligands system HVEM, LIGHT, CD160 and BTLA (CD272) is part of a complex network of overlapping receptor interactions.<\/p>\n","protected":false},"author":13,"featured_media":8224,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10,1,637],"tags":[279,185,7,683,685],"class_list":["post-8218","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-general-information","category-t-cells","tag-adipogen","tag-antibodies","tag-cancer","tag-proteins","tag-t-cells-2"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8218","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=8218"}],"version-history":[{"count":5,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8218\/revisions"}],"predecessor-version":[{"id":8225,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/8218\/revisions\/8225"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media\/8224"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=8218"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=8218"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=8218"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}